24/7 Market News Snapshot 07 October, 2025 – Adicet Bio, Inc. Common Stock (NASDAQ:ACET)

October 7, 2025

DENVER, Colo., 07 October, 2025 (www.247marketnews.com) – (NASDAQ:ACET) are discussed in this article.
Adicet Bio, Inc. (ACET) has emerged as a significant player in the biotechnology sector, reporting a notable surge in its stock price, which reached $1.313 in pre-market trading, representing a remarkable increase of 31.3% from the prior close of $1.000. This rapid growth is underscored by robust trading activity, with nearly 2 million shares exchanged, reflecting heightened investor enthusiasm and potentially positive market perceptions of the company’s future prospects.

In addition to the thriving stock performance, Adicet Bio is also generating excitement in the medical research community with its recent announcement regarding initial findings from a Phase 1 trial of ADI-001, an allogeneic gamma delta T cell therapy. Preliminary results indicate promising safety and efficacy, as all seven participants in the trial—including five with lupus nephritis and two with systemic lupus erythematosus—achieved either disease remission or stabilization. As a result, these patients were able to reduce or discontinue reliance on immunosuppressants.

The trial data, evaluated up to August 31, 2025, did not report any serious adverse events, demonstrating an encouraging safety profile for ADI-001, though two instances of mild cytokine release syndrome were observed. Given the positive preliminary results, Adicet Bio plans to engage regulatory authorities to discuss the advancement to a pivotal Phase 2 trial targeting lupus conditions, anticipated to commence mid-2026.

President and CEO Chen Schor emphasized the transformative potential of ADI-001 in treating autoimmune diseases, expressing optimism about its capability to effectively reset the immune system. With over 25 clinical sites now active and a strategic focus on expanding investigations into additional autoimmune disorders, Adicet Bio is poised for significant milestones in 2026, reinforcing its commitment to pioneering innovative therapies for patients facing these challenging health issues.

Related news for (ACET)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.